BIOMAT Database Logo BIOMAT Database Logo

An economical regimen of human diploid cell strain anti-rabies vaccine for post-exposure prophylaxis. 1983

M J Warrell, and D A Warrell, and P Suntharasamai, and C Viravan, and A Sinhaseni, and D Udomsakdi, and R Phanfung, and C Xueref, and J C Vincent-Falquet, and K G Nicholson, and D Bunnag, and T Harinasuta

Vaccine regimens using 0.1 ml human diploid cell strain vaccine (HDCSV) given intradermally (id) in single and multiple sites, or with aluminum hydroxide adjuvant given subcutaneously (sc), were compared with the regimens of HDCSV and Semple vaccine currently suggested by WHO. Some groups were also given human rabies-immune globulin (HRIG). Neutralising antibody titres were monitored for 3 months. Antibody was detected earliest in subjects given 0.1 ml HDCSV id at each of eight sites. The highest antibody titres from day 14 onwards were found after intramuscular (im) administration of HDCSV, but the multiple-site id regimen, which requires only one quarter of the volume of vaccine required for the im regimen, gave similar results, provided that a booster was given on day 91. This finding suggests that a treatment schedule based on this regimen would be suitable for post-exposure prophylaxis. Adjuvanted vaccine gave similar results to the same amount of antigen given id. Semple vaccine produced the lowest titres. HRIG, given at the high dose of 40 IU per kg, suppressed the antibody response to some of the regimens.

UI MeSH Term Description Entries
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D007271 Injections, Intradermal The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer. Intradermal Injections,Injection, Intradermal,Intradermal Injection
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011818 Rabies Acute VIRAL CNS INFECTION affecting mammals, including humans. It is caused by RABIES VIRUS and usually spread by contamination with virus-laden saliva of bites inflicted by rabid animals. Important animal vectors include the dog, cat, bat, fox, raccoon, skunk, and wolf. Encephalitic Rabies,Furious Rabies,Hydrophobia,Paralytic Rabies,Lyssa,Furious Raby,Lyssas,Rabies, Encephalitic,Rabies, Furious,Raby, Furious
D011819 Rabies Vaccines Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis. Rabies Human Diploid Cell Vaccine,Rabies Vaccine,Vaccine, Rabies,Vaccines, Rabies
D011820 Rabies virus The type species of LYSSAVIRUS causing rabies in humans and other animals. Transmission is mostly by animal bites through saliva. The virus is neurotropic multiplying in neurons and myotubes of vertebrates. Rabies viruses
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random

Related Publications

M J Warrell, and D A Warrell, and P Suntharasamai, and C Viravan, and A Sinhaseni, and D Udomsakdi, and R Phanfung, and C Xueref, and J C Vincent-Falquet, and K G Nicholson, and D Bunnag, and T Harinasuta
An effective economical intradermal regimen of human diploid cell rabies vaccination for post-exposure treatment.
March 1986, Clinical and experimental immunology,
M J Warrell, and D A Warrell, and P Suntharasamai, and C Viravan, and A Sinhaseni, and D Udomsakdi, and R Phanfung, and C Xueref, and J C Vincent-Falquet, and K G Nicholson, and D Bunnag, and T Harinasuta
Human diploid cell strain vaccine for post-exposure rabies treatment.
March 1985, The Journal of communicable diseases,
M J Warrell, and D A Warrell, and P Suntharasamai, and C Viravan, and A Sinhaseni, and D Udomsakdi, and R Phanfung, and C Xueref, and J C Vincent-Falquet, and K G Nicholson, and D Bunnag, and T Harinasuta
Post-exposure prophylaxis against rabies in children with human diploid cell vaccine.
August 1982, Lancet (London, England),
M J Warrell, and D A Warrell, and P Suntharasamai, and C Viravan, and A Sinhaseni, and D Udomsakdi, and R Phanfung, and C Xueref, and J C Vincent-Falquet, and K G Nicholson, and D Bunnag, and T Harinasuta
Human diploid-cell-culture vaccine for rabies prophylaxis.
May 1979, Canadian Medical Association journal,
M J Warrell, and D A Warrell, and P Suntharasamai, and C Viravan, and A Sinhaseni, and D Udomsakdi, and R Phanfung, and C Xueref, and J C Vincent-Falquet, and K G Nicholson, and D Bunnag, and T Harinasuta
Possible factors influencing unsuccessful protection of post-exposure prophylaxis for rabies by human diploid cell vaccine.
July 1985, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
M J Warrell, and D A Warrell, and P Suntharasamai, and C Viravan, and A Sinhaseni, and D Udomsakdi, and R Phanfung, and C Xueref, and J C Vincent-Falquet, and K G Nicholson, and D Bunnag, and T Harinasuta
Post-exposure use of human diploid cell culture rabies vaccine.
January 1976, Developments in biological standardization,
M J Warrell, and D A Warrell, and P Suntharasamai, and C Viravan, and A Sinhaseni, and D Udomsakdi, and R Phanfung, and C Xueref, and J C Vincent-Falquet, and K G Nicholson, and D Bunnag, and T Harinasuta
Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV).
May 2011, Vaccine,
M J Warrell, and D A Warrell, and P Suntharasamai, and C Viravan, and A Sinhaseni, and D Udomsakdi, and R Phanfung, and C Xueref, and J C Vincent-Falquet, and K G Nicholson, and D Bunnag, and T Harinasuta
Pre-exposure prophylaxis against rabies in children by human diploid cell vaccine.
March 1984, Lancet (London, England),
M J Warrell, and D A Warrell, and P Suntharasamai, and C Viravan, and A Sinhaseni, and D Udomsakdi, and R Phanfung, and C Xueref, and J C Vincent-Falquet, and K G Nicholson, and D Bunnag, and T Harinasuta
[Post exposure use of human diploid cell culture rabies vaccine (author's transl)].
December 1977, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie und Parasitologie,
M J Warrell, and D A Warrell, and P Suntharasamai, and C Viravan, and A Sinhaseni, and D Udomsakdi, and R Phanfung, and C Xueref, and J C Vincent-Falquet, and K G Nicholson, and D Bunnag, and T Harinasuta
Some experiences with human diploid cell strain-(HDCS) rabies vaccine in pre- and post-exposure vaccinated humans.
January 1978, Developments in biological standardization,
Copied contents to your clipboard!